CeriBell, Inc. (NASDAQ:CBLL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $22.20.

Several brokerages have commented on CBLL. Canaccord Genuity Group decreased their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. Finally, BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th.

Insiders Place Their Bets

In other CeriBell news, CEO Xingjuan Chao sold 39,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $20.10, for a total value of $783,900.00. Following the sale, the chief executive officer owned 836,347 shares in the company, valued at $16,810,574.70. The trade was a 4.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Raymond Woo sold 11,104 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $20.44, for a total transaction of $226,965.76. Following the completion of the sale, the chief technology officer owned 197,648 shares in the company, valued at approximately $4,039,925.12. The trade was a 5.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 158,405 shares of company stock worth $2,971,979 in the last 90 days. 20.10% of the stock is currently owned by corporate insiders.

Institutional Trading of CeriBell

Large investors have recently made changes to their positions in the business. Emerald Mutual Fund Advisers Trust increased its holdings in shares of CeriBell by 58.2% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock worth $1,785,000 after buying an additional 57,175 shares during the last quarter. CenterBook Partners LP increased its holdings in shares of CeriBell by 448.0% in the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock worth $5,476,000 after buying an additional 389,584 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of CeriBell by 8.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock worth $4,724,000 after buying an additional 31,177 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of CeriBell in the 3rd quarter worth about $158,000. Finally, TimesSquare Capital Management LLC increased its holdings in shares of CeriBell by 2.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock worth $9,395,000 after buying an additional 20,700 shares during the last quarter.

CeriBell Stock Up 0.2%

Shares of CBLL stock opened at $18.77 on Friday. The stock has a market cap of $712.19 million, a P/E ratio of -11.52 and a beta of 0.99. CeriBell has a 52 week low of $10.85 and a 52 week high of $24.33. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The company’s fifty day simple moving average is $19.08 and its two-hundred day simple moving average is $19.08.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The company had revenue of $26.49 million during the quarter, compared to analysts’ expectations of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Analysts predict that CeriBell will post -1.69 EPS for the current fiscal year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.